Poster Session M - Cardiovascular Medicine and Research 1.
Introduction: The Hungarian Society of Hypertension has initiated a nationwide program to promote the routine use of the ambulatory blood pressure monitoring (ABPM).
Methods: open-label, multicenter, ongoing, observational study. Adult (age >18 years) patients with known hypertension (HT), or with suspected hypertension (nHT) can be involved in the study. 40621 ABPMs were performed between 21.02.2021-16.11.2023 with Meditech ABPM-06 monitors. 1901 patients were excluded from the analysis due to protocol deviation.
Results: 26315 patients were HTs (68.3%), 12193 patients were nHTs (31.5%). In the HT group 95.5%, in the nHT group 21.5% were treated. 63.6% of all patients were hypertensives according to the 24-hour average(24h) blood pressure(BP) values. 24h systolic and diastolic BP was 133.84±14.5 mmHg and 79.2±10.3 mmHg, respectively. There was no difference in the 24h systolic BP between HT and nHT patients (133.75±13.96 mmHg vs. 133.86±14.72 mmHg, p=NS). Obesity(BMI≥30 kg/m2)(OR=1.82[1.73;1.92]24h), coffee consumption(>3/day)(OR= 1.22[1.16;1.29]24h), snoring(OR= 1.39[1.33;1.46]24h) and smoking (OR=1.10[1.03;1.18]24h) all increased the risk of hypertension. These factors primarily affecting more the daytime(D)-, than the nighttime(N) BP values (coffee consumption: OR=1.24[1.18;1.31]D, OR=1.13[1.07;1.19]N; snoring: OR=1.42[1.36;1.49]D, OR=1.31[1.25;1.38]N; smoking: OR=1.09[1.01;1.16]D, OR=1.01[0.94;1.08]N(NS)). Lack of regular sport(<3x30 minutes weekly) primarily increased the risk of nighttime elevated BP values (OR=1.11[1.05;1.18]24h, OR=1.19[1.12;1.26]N, OR= 1.02[0.96;1.07]D(NS)).
Conclusion: Hypertension is highly prevalent in both HT and nHT patients with ABPM-monitoring, irrespectively of gender or treatment. Obesity, lack of regular sport, coffee consumption, snoring and smoking are all significant risk factors in developing hypertension, latter ones affecting more the daytime BP values, whereas lack of regular sport affects more the nighttime BP values.
Funding: The Hungarian Society of Hypertension, Egis Pharmaceuticals